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Due to itspotential asaneﬀective, needle-free route ofimmunizationforusewithsubunitvaccines,nasalimmunizationcontinues
to be evaluated as a route of immunization in both research and clinical studies. However, as with other vaccination routes,
subunit vaccines often require the addition of adjuvants to induce potent immune responses. Unfortunately, many commonly
used experimental vaccine adjuvants, such as cholera toxin and E. coli heat-labile toxin, are too toxic for use in humans. Because
new adjuvants are needed, cytokines have been evaluated for their ability to provide eﬀective adjuvant activity when delivered by
the nasal route in both animal models and in limited human studies. It is the purpose of this paper to discuss the potential of
cytokines as nasal vaccine adjuvants.
1.Introduction
The nasal route of immunization is an attractive route of im-
munization for several reasons. Perhaps most importantly,
this route of immunization does not require needles, and the
WHO is interested in needle-free methods of immunization
because needle reuse can lead to disease transmission [1–
5]. Intranasal immunization would also allow people with
a needle phobia to receive vaccines that they may otherwise
avoid, increasing the chances of establishing herd immu-
nity [6–8]. Finally, nasal immunization has the ability to
induce antigen-speciﬁc immunity in both the systemic and
mucosal compartments (humoral and cellular), while par-
enteralimmunization rarely induces mucosalimmunity. The
induction of antigen-speciﬁc mucosal immunity (including
secretory IgA) may provide an added layer of protection
against pathogens that ﬁrst contact the host at a mucosal
surface [9–11].
As with other routes of immunization, in the absence of
potent vaccine antigens, such as live-attenuated organisms
(virus, bacteria), vaccine adjuvants are required to boost the
immune responses to less potent antigens, such as recom-
binant subunit proteins. Unfortunately, some of the most
commonly used experimental mucosal vaccine adjuvants are
not safe for use in humans. The most notable example is
cholera toxin (CT). Although CT is considered to be the
“gold-standard” mucosal vaccine adjuvant, amounts as low
as 2.5μg delivered intranasally can induce antigen-speciﬁc
IgE [12]. In addition, even mutant CT has been shown to
redirectthecodeliveredvaccineantigentotheolfactorynerve
and bulb of the brain in mice [13, 14]. Escherichia coli heat-
labile toxin (LT) has also been shown to have negative side
eﬀects in humans, as both native and mutant LT (mLT) used
as adjuvants were recently associated with the development
of Bell’s palsy following intranasal delivery in humans [15–
17]. It is, therefore, evident that these toxin adjuvants exhibit
safety concerns that will likely prevent their use in nasally
delivered vaccines for humans.
Since the early 1990s, many groups, including ours, have
examined the ability of cytokines to serve as vaccine adju-
vants due to their potent eﬀects on the immune system. The
use of cytokines as vaccine adjuvants has been previously
reviewed [18–20] ,b u tw eh o p et oo ﬀer a more in-depth and
up-to-date review on the use of cytokines as nasal vaccine
adjuvants.
It is the purpose of this paper to highlight the immune
responses that can be augmented by the use of cytokines as
nasal vaccine adjuvants. We will discuss the ability of nasally2 Clinical and Developmental Immunology
delivered cytokine adjuvants to induce antigen-speciﬁc se-
rum antibody, mucosal antibody, and cell-mediated immu-
nity as well as to induce protection against a challenge with
toxins or live bacteria/viruses. Although some of the studies
discussed have focused on responses other than those high-
lighted, including cell traﬃcking and lymphocyte cell-sur-
face molecule expression proﬁles, this paper will focus on
vaccine-induced adaptive immune responses augmented by
the use of cytokines as adjuvants for nasal vaccines. When
possible,theadjuvantactivityofcytokineswillbehighlighted
by discussion of the antigen-speciﬁc immune responses
induced in the absence of adjuvants and compared to the
antigen-speciﬁc responses induced with the use of cytokine
adjuvants. It is important to note that comparing antigen-
speciﬁc immune responses between studies is sometimes dif-
ﬁcult given that few use the same procedures for measuring
and calculating the induced responses. For instance, ELISA
valuesmeasured usingasingle sample dilutionandreporting
OD values are not as sensitive as endpoint titers, and it is
therefore diﬃcult to compare ELISA results between studies
reporting endpoint titers and those reporting OD (Table 1).
2.IL-12
IL-12 is commonly known as a Th1 cytokine. It induces NK,
T, and B cellsto produceIFNγ, and it is the primary cytokine
involved in Th1 diﬀerentiation [35].
2.1. Serum Antibody Production. When used as a nasal vac-
cine adjuvant, IL-12 has been shown by several groups to
enhance serum antibody production, including IgM, IgG,
and IgA, to a variety of antigens. However, IL-12 has been
used at a variety of doses and dosing schedules with a
variety of outcomes. For instance, Bradney et al. delivered
0.1μgI L - 1 2+1 0 μg HIV peptide to mice on days 0,
7, 14, and 28 but failed to see an increase in antipeptide
IgG GMT compared to serum anti-HIV peptide IgG titers
in mice immunized with peptide alone [31]. By contrast,
Baca-Estrada et al. delivered 0.5μgI L - 1 2o nd a y s0a n d
21 with 0.8μg herpesvirus type 1 glycoprotein-D- (gD-)-
containing liposomes and noted a signiﬁcant increase in
anti-gD serum IgG compared to immunization with gD-
containingliposomesalone(∼1:75,000versusundetectable)
[26]. The use of IL-12 in this nasal vaccine formulation also
signiﬁcantly increased serum bovine herpesvirus neutraliz-
ing antibody titers (approx. 1:650 versus undetectable in
the absence of IL-12) [26]. Using a more complex dosing
schedule that would not likely be relevant for human vaccine
design, Boyaka et al. demonstrated increases in serum anti-
TT IgG and IgA following vaccination with 1μg liposome-
complexedIL-12deliveredondays0, 3,7,10,14,and 17with
20μg TT delivered on days 0, 7, and 14 (approx. IgG titers of
1:2,097,152 versus 1:4,096 and IgA titers of 1:2,048 versus
1:32, resp.) [25]. In fact, the majority of studies delivering
recombinant IL-12 (rIL-12) have used doses of 1μg, albeit
with diﬀerent total amounts and dosing schedules. Several
studies have also examined the ability of IL-12 incorporated
into a plasmid to induce immune responses [30]. Although
it is diﬃcult to compare doses between those studies and
studies delivering rIL-12, all forms of IL-12 have consistently
been shown to increase antigen-speciﬁc IgG2a and decrease
antigen-speciﬁc IgG1 antibody production compared to
antigen delivered alone [30, 36, 37], indicating that its coad-
ministration with vaccine antigens induces a Th1 bias in the
immune response. This is unsurprising given its in vivo role
in immune response development.
Very few studies delivering IL-12 with antigen have com-
pared the IL-12-induced antibody response to the response
induced by more common vaccine adjuvants, such as CT.
Unfortunately, the few studies that have included CT as a
control adjuvant did not observe signiﬁcant increases in the
antigen-speciﬁcantibodytiterwhenusingIL-12ascompared
to antigen alone [30, 31, 38]. Although Okada et al. reported
signiﬁcant increases in anti-HIV IgG2a following IL-12 +
antigenimmunization, theyonlycompared theantigen+IL-
12-induced anti-HIV total IgG responses to those induced
by antigen + 10μg CT; neither group induced a signiﬁcant
increase in anti-HIV IgG when compared to serum antibody
titers measured in mice immunized with antigen alone [30].
Albu et al. also compared the antigen-speciﬁc IgG response
induced by vaccination with antigen + IL-12 or CTB [38],
and they also failed to detect an increase in antigen-speciﬁc
antibody with either adjuvant. It is, therefore, diﬃcult to
determine the signiﬁcance of IL-12-induced antigen-speciﬁc
serum antibody production with respect to other well-
known adjuvants.
IL-12 has also frequently been used in combination with
otheradjuvants. AlthoughBrandtzaegfailed toobserveadju-
vant activity when IL-12 was administered nasally to mice
with an HIV peptide antigen, they did observe an increase in
serum antipeptide IgG when mice were nasally immunized
with HIV peptide combined with 0.1μgr I L - 1 2m i x e dw i t h
IL-1 and IL-18 [10]. Similarly, Mutsch et al. demonstrated
that 0.1μg rIL-12 incorporated into a vaccine already
containing1μgCTcouldenhanceanti-TT IgG2aproduction
and inhibit anti-TT IgE [17]. These observations suggest
that low-dose rIL-12 may be useful to enhance the adjuvant
activity of other adjuvants while simultaneously enhancing
IgG2a/Th1 responses.
2.2. Mucosal Antibody Production. Several studies have de-
monstrated the ability of rIL-12 to induce mucosal IgA pro-
duction to a variety of codelivered antigens. However, unlike
many of the studies that examined serum antibody pro-
duction, a number of studies examining mucosal antibody
productionwith rIL-12 haveused alternatedosingschedules,
with IL-12 delivery given both with the vaccine and then
at various time points following vaccination. For instance,
Boyaka et al. delivered 1μg liposome-complexed IL-12 to
mice on days 0, 3, 7, 10, 14, and 17 with an antigen delivery
schedule of 0, 7, and 14 [25]. Using this schedule, they
inducedthe productionoffecal(1:512),vaginal (1:23),and
salivary (1:64) anti-TT IgA that was signiﬁcantly increased
when compared to anti-TT IgA responses induced by immu-
nization with TT alone (∼1:4). They also noted signiﬁcant
IL-12-dependent increases in IgA AFCs in the lungs, CLNs,Clinical and Developmental Immunology 3
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and lamina propria lymphocytes (19, 15, and 934 versus
1, 1, and 23 AFC/106 cells, resp.). Similarly, Lynch et al.
delivered1μgIL-12ondays0,1,2,and 3withpneumococcal
polysaccharide (PPS3) delivery on day 0. Using this dosing
schedule, they noted a signiﬁcant increase in BAL anti-PPS3
IgA, but this was reported only as an OD increase at an
undeﬁned BAL dilution [37]. Interestingly, using a similar
dosing schedule to Lynch et al., with antigen delivery on day
0a n dI L - 1 2d e l i v e r yo nd a y s0 ,1 ,2 ,a n d3 ,A r u l a n a n d a m
and Metzger observed a signiﬁcant decrease in fecal anti-
OVA IgA production; this was also reported only as a change
in OD at an undeﬁned fecal extract dilution [36]. Baca-
Estrada et al. used a more typical dosing schedule of 0 and
21 days with antigen-containing liposomes and free IL-12;
although absoluteincreases in lungantigen-speciﬁc IgA were
noted (Ag alone, 1:66; Ag + free IL-12, 1:577), the increases
were not signiﬁcant due to large amounts of animal-to-
animal variation [26]. Unfortunately, the diﬀerent methods
of measuring the immune response between the studies
makes it diﬃcult to compare their results because Boyaka
etal.and Baca-Estrada etal.weretheonlygroupstocalculate
endpoint titers for mucosal antibody responses following
vaccination with antigen + IL-12 only. Nonetheless, it does
appear that IL-12 has the potential to increase mucosal IgA
production, but more studies need to be carried out to
conﬁrm this, including studies comparing IL-12 to more
well-known mucosal adjuvants.
2.3. Cell-Mediated Immunity. As a Th1-associated cytokine,
IL-12 has been evaluated for its ability to induce CD8+
cytotoxic T lymphocytes as well as delayed-type hypersen-
sitivity reactions. The groups that have examined the ability
of IL-12 to induce these responses have used three diﬀerent
forms of IL-12, including recombinant protein [39], plasmid
expressed [30, 40], and bacterium expressed [41]. Using
0.1μg rIL-12 as an adjuvant coadministered with an HIV
peptide immunogen, we observed no signiﬁcant increase
in peptide-speciﬁc lysis compared to mice immunized with
antigen alone at a variety of antigen doses at an E:T ratio
of 25:1 [39]. In this same study, CT used as a positive
control adjuvant induced ∼40–60% peptide-speciﬁc lysis.
We also failed to see an increase in the number of peptide-
speciﬁc IFNγ-secreting CD8+ T cells. By contrast, when
Berm´ udez-Humar´ an et al. immunized mice with a recombi-
nant lactococci secreting the HPV E7 protein and IL-12, cell-
mediated cytotoxicity was signiﬁcantly increased compared
to cytotoxic T lymphocyte (CTL) responses induced by
vaccination with a recombinant lactococci secreting only
E7 (∼15% versus 5%, resp.) at an E:T ratio of 30:1 [41].
Using the same formulation, they also observed signiﬁcant
increases in the numbers of antigen-speciﬁc IFNγ-secreting
CD4+ and CD8+ T cells over those induced by antigen
alone (CD8:200 versus 100 per 104 cells, CD4: 225 versus
50 per 104 cells). Considering that the % lysis we reported
following immunization with peptide alone was near 15%,
it is possible that the diﬀerences between our study and
Berm´ udez-Humar´ an’s lay in the type of antigen (protein
versus peptide) or the potency of the antigen.
Codelivering10μgofaplasmidexpressing IL-12and2μg
each of two HIV protein-expressing plasmids, Xin et al.
demonstrated signiﬁcantly increased antigen-speciﬁc lysis
compared to that induced by immunization with antigen
alone at an E:T ratio of 20:1 (∼45% versus <20%, resp.)
following only one vaccination [40]. When Okada et al.
included 2 μg of pIL-12 in a vaccine formulation with lipo-
somes and plasmid-expressed antigen delivered three times,
they also observed an increase in the antigen-speciﬁc lysis
at an E:T ratio of 25:1 when compared to antigen plus
liposomes [30]. However, they did not compare the ability
of IL-12 to increase speciﬁc lysis in the absence of liposomes.
It is interesting to note that although we did not observe a
signiﬁcant increase in antigen-speciﬁc lysis following three
immunizations with antigen + IL-12, adding an additional
boost with antigen alone (∼10% versus <5%, resp.) resulted
in a signiﬁcant increase in antigen-speciﬁc lysis compared to
antigen alone delivered four times (at an E:T ratio of 20:1).
Given that we delivered a total of 0.3μg IL-12 over the three
immunizations, it is likely that we also delivered the lowest
doseofIL-12ofthestudiesreportedhere.HadtheIL-12dose
been optimized and increased into the ranges used by other
studies to induce serum antibody production, it is possible
that a stronger eﬀect of IL-12 on speciﬁc lysis would have
been seen. However, three of the four studies discussed here
did observe signiﬁcant increases compared to antigen alone
(or plus liposomes) when IL-12 was added to the vaccine
formulation.
2.4. Protection against Challenge. The ability of IL-12 to
augment vaccine-induced immune responses and enhance
protection against infectious challenge has been evaluated
using both viral and bacterial challenge models. Two weeks
following intranasal immunizations ondays0,7,and14with
a TT vaccine, Boyaka et al. challenged mice with 100 MLDs
(minimum lethal doses) of TT. All mice that received the
vaccine formulation with TT + liposome-complexed IL-12
(1μg delivered on days 0, 3, 7, 10, 14, and 17) survived the
challenge; none of themice receiving TT alone survived [25].
Following one vaccination with a pneumococcal conjugate
vaccine (day 0) and 1μg IL-12 on days 0, 1, 2, and 3,
Lynch et al. challenged mice with 5 × 104 CFU type 3
pneumococcal bacteria. Although the vaccination regimen
did not induce complete protection against challenge, nearly
80% of mice that received the vaccine and IL-12 survived the
challenge, compared to 40% survival of those that received
the vaccine only [37]. Using a diﬀerent approach, Parker et
al. evaluated the ability of vaccination with IL-12-expressing
HSV-1 toprotectagainst systemic challenge with 100LD90 of
a highly pathogenic HSV strain [42]. Mice immunized with
asfewas100pfuHSV/IL-12hadsigniﬁcantlygreatersurvival
than sham-immunized mice (0/29). At this dose, 4/19 mice
survived compared to 0/19 mice immunized with the parent
virus. As the immunization dose increased, so did survival
following challenge, with 92%and 100% ofmice immunized
with 10,000 and 100,000 pfu surviving challenge, compared
to 30% and 80% of mice immunized with the parent strain.
Although only a few studies have evaluated the ability ofClinical and Developmental Immunology 5
IL-12 to induce protective immunity, it does appear to be
eﬀective in this regard.
3.IL-2
IL-2 also involved in T-cell proliferation and the induction
of T regulatory responses [43]. As such, it has typically been
investigated for its ability to induce CTLs (see below), but
its ability to induce serum antibody production has been ex-
amined by a small number of groups.
3.1. Serum Antibody Production. In two separate studies, Xin
et al. demonstrated that a single administration of plasmid-
incorporated IL-2 to mice induced signiﬁcant decreases in
serum anti-HIV IgG1 and increases in serum anti-HIV
IgG2a (16- and 10-fold, resp., compared to antigen alone)
following codeliverywithtwootherplasmidsexpressing HIV
proteins [40, 44]. Steidler et al. took a diﬀerent approach
and engineered a recombinant L. lactis that coexpressed IL-2
and tetanus toxin fragment C (TTFC) [23]. Following nasal
inoculation on days 0, 14, and 28 with 109 bacteria, the IL-2-
expressing bacterium induced signiﬁcant increases in serum
anti-TTFC IgG on days 24, 35, and 80 postprimary immu-
nization (approx. 10-, 10-, and 5-fold higher than TTFC-
expressing bacteria alone).
Macaques have also been used to examine the eﬀective-
ness of IL-2 as a nasal vaccine adjuvant [45]. Following four
nasal immunizations with 1.5mg DNAcontaining amutated
SIVmac239 genome and IL-2, macaques were challenged
rectally, and serum antibody responses were then monitored.
At 6–8 weeks after the challenge, animals immunized with
IL-2 had signiﬁcantly greater gp120- and gp41-speciﬁc IgG
(∼1:50,000) than those given no incorporated cytokine
(∼1:1,000) or incorporated IL-12 (∼1:5,000); by 12–16
weeks, animals receiving IL-2 had also increased anti-
SIV IgG compared to the other immunization groups
(∼1:50,000versus ∼1:8,000)[45].Thisstudyalsoevaluated
the ability of IL-2 to augment virus-neutralizing antibodies
and demonstrated a nearly 50-fold increase from ∼1:100
in antigen-alone immunized macaques to ∼1:50,000 in
macaques immunized with the vaccine formulated with IL-
2. Although this study used a slightly diﬀerent approach,
examining antibody titers after challenge, the results indicate
that IL-2 is eﬀective at inducing serum antigen-speciﬁc and
neutralizing antibody production in nonhuman primates
and demonstrates the eﬃcacy of IL-2 used as a nasal vaccine
adjuvant.
3.2. Mucosal Antibody Production. Of the numerous studies
that have examined intranasal delivery of IL-2, only a few
have examined mucosal antibody production. Two such
studies were performed in mice by Abraham and Shah [46]
and Ferko et al. [24]u s i n gv e r yd i ﬀerent delivery methods.
While Abraham and Shah used a liposomal formulation to
deliver 25μg levan (a bacterial polysaccharide) and 0.02–
0.2μg IL-2, Ferko et al. delivered 2 × 105 PFU of an IL-
2-expressing inﬂuenza virus (ca Sing-IL-2). Unlike many
studies involving other nasally delivered cytokine adjuvants,
Abraham and Shah noted an increase in the total number
of pulmonary antibody-secreting plasma cells (ASCs) (from
3,712 to ∼7,480 per set of lungs) in addition to an increase
in the number of levan-speciﬁc ASCs (undetectable to ∼330
perset oflungs),ofwhich 90%were antilevan IgA ASCs.The
amount ofantilevan IgAin lunglavageswasalso signiﬁcantly
increased at both 0.02 and 0.2μg IL-2, but these increases
were only presented as signiﬁcant increases in OD at a 1/3
dilution. Following delivery of ca Sing-IL-2, Ferko et al. also
demonstrated a 3.5-fold increase in the production of nasal
virus-speciﬁc IgA (1:50 for ca Sing versus 1:200 for ca
Sing-IL-2) and a 2-fold increase in vaginal virus-speciﬁc IgA
compared to ca Sing (1:200 and 1:400, resp.).
In addition to the studies in mice, one group has also ex-
amined the impact of IL-2 incorporation into an avian in-
ﬂuenza virus vaccine in chickens [47]. In this study, chickens
were immunized twice (days 0 and 14) with approximately
105 EID50 H5N2 with or without 50μgI L - 2 .I nt h el u n ga n d
trachea, the total number of IgA and IgG ASCs increased
signiﬁcantly at weeks 3, 5, and 7 following vaccination with
virus + IL-2 compared to vaccination with virus alone. How-
ever, this study did not examine the impact of vaccination on
virus-speciﬁc ASCs or IgA, and the number of IgA-secreting
cells was counted in ﬁxed tissue sections instead of in an
ELISPOT assay. In contrast to many of the studies using a
mouse model, however, Xiawen et al. compared the adjuvant
activity of IL-2 to an equivalent dose of CpG. CpG and IL-
2 induced statistically equivalent amounts of IgA-secreting
cells at all time points examined. Although IL-2 induction of
mucosal IgA responses has not been often examined, studies
thus far are encouraging.
3.3. Cell-Mediated Immunity. Using an inﬂuenza virus ex-
pressing IL-2, Ferko et al. induced a twofold increase in the
number of antigen-speciﬁc IFN-γ-secreting cells in both the
spleen and lymph nodes of immunized mice 10 days after
the primary immunization and a nearly fourfold increase
in the mediastinal lymph nodes 4 weeks after the primary
immunization compared to IFNγ responses induced by
immunization with virus alone [24]. In addition, two studies
by Xin et al. demonstrated signiﬁcantly increased target cell
lysis following delivery of 10μg pIL-2 at E:T ratios of both
20:1 and 80:1 (increases of ∼40% and ∼30% compared
to lysis induced by immunization with plasmid-expressed
antigen alone) [40, 44]. They also demonstrated signiﬁcant
increases in DTH following codelivery of 1 or 10μgp I L -
2 compared to antigen alone (14.2 and 16.7 versus 11.1 ×
10−2 mm, resp.).
3.4. Protection against Challenge. The ability of IL-2 to in-
duce protective immune responses when intranasally code-
livered with a vaccine has been evaluated in both mouse and
monkeymodels.Usingamousemodelofinﬂuenzainfection,
Ferko et al. evaluated the ability of immunization with
an IL-2-expressing inﬂuenza virus to protect mice against
challenge with 2 × 105 pfu of the Sing-WT virus [24]. The
addition of IL-2 to the vaccine provided 100% protection
while immunization with virus alone provided only 57%6 Clinical and Developmental Immunology
protection. ca Sing-IL-2 also decreased the viral titer in the
lungs from 620 (ca Sing) to <86 TCID50/g tissue. Similarly,
in a bacterial challenge model, Abraham and Shah increased
survival following challenge with 5 × 107 cfu P. aeruginosa
from ∼10% in those receiving antigen-containing liposomes
to 45% in those receiving liposomes-containing antigen and
IL-2 [46].
In a macaque model of SIV infection, Bertley et al. used
CD4+ T cell counts as a marker of disease progression fol-
lowing rectal challenge with 10 50% animal infectious doses
(ID50) of pathogenic SHIV89.6P virus [45]. Four nasal im-
munizations with 1.5mg DNA containing a mutated SIV-
mac239 genome and IL-2 did not signiﬁcantly increase the
CD4+TcellcountcomparedtothosereceivingtheDNAvac-
cinealone.TheadditionofIL-2did,however,providegreater
protection than the vaccine formulation that includedIL-12,
as5/5animals immunized withantigenandIL-2survivedthe
challenge, while only 1/5 animals immunized with antigen
and IL-12 survived. Interestingly, 4/5 animals receiving the
DNA vaccine alone and 1/5 of the nonimmunized ani-
mals survived; two of the macaques receiving the DNA vac-
cine alone seroconverted, and viremia was never detected.
Although the DNA vaccine alone was eﬀective at pro-
tecting some of the animals, IL-2 does appear to have
provided some level of increased protection in this model as
well.
4.IL-15
IL-15isknowntoshareseveraloverlappingactivitieswithIL-
2, which is likely due to their extremely high homology and
their structural similarities [48]. In addition to its ability to
promote both NK and T-cell development and proliferation
[48], IL-15 is known to augment B-cell antibody produc-
tion, and so its incorporation into nasal vaccines could be
beneﬁcial [49].
4.1. Serum Antibody Production. Two studies investigating
the ability of IL-15 to provide nasal vaccine adjuvant activity
have shown similar results. Toka et al. delivered 50μgI L - 1 5
and 50μg of DNA encoding herpesvirus glycoprotein B (gB)
to mice on days 0 and 21. At 64 days after the boost, the
incorporation of IL-15 did not signiﬁcantly increase serum
anti-gB IgG titers compared to gBDNA alone (1:22,000
versus 1:19,061, resp.) [27]. When Xin et al. delivered one
dose of 2μg pCMV160IIIB/REV + 10–50μg IL-15 plasmid,
although serum anti-HIV IgG2a titers were signiﬁcantly
increased compared to antigen alone, the real change in titer
was small (1:32versus 1:11),and serum anti-HIV IgG titers
were unchanged [40].GiventhatXinetal.didseeanincrease
(albeit small) in serum anti-HIV IgG2a, it is possible that
Toka and Rouse could have seen increased anti-gB IgG2a
titers had they been investigated. However, it is diﬃcult to
compare the two studies given the diﬀerent forms of IL-15
and the diﬀerent dosing schedules.
4.2. Mucosal Antibody Production. Two studies have evalu-
atedIL-15foritsabilitytoaugmentvaccine-inducedmucosal
IgA, although they provide conﬂicting results. Following
the administration of 50μgI L - 1 5D N Aw i t h5 0μgg B D N A ,
Toka and Rouse noted a fourfold increase in vaginal anti-
gB IgA when compared to the vaginal anti-gB IgA response
induced by immunization with gBDNA alone. The elevated
vaginal IgA response persisted for 300 days [27]. By contrast,
using 2μg pCMV160IIIB/REV plasmid and 10μgp l a s m i d -
encodedIL -15,Xinetal.failedtoseeanincr easeinfecalanti-
HIVIgA.Thereareseveralpossiblereasons fortheseconﬂict-
ing results. Although both groups immunized with plasmid-
encoded IL-15, it is diﬃcult to compare the actual delivered
dose of cytokine. In addition, Toka and Rouse investigated
vaginal IgA production, while Xin et al. evaluated fecal IgA
production. Although nasal immunization can induce the
production of fecal IgA, it more commonly induces IgA
production in the respiratory and reproductive tracts [50,
51]. It is, therefore, not surprising that Xin et al. failed to
s e ea ni n c r e a s ei na n t i - H I Vf e c a lI g Aw i t ht h eu s eo fI L -
15 as an adjuvant when compared to mice immunized with
antigen alone. Nonetheless, studies examining the ability of
IL-15 to induce mucosal antibody production at more sites
with a larger number of antigens are required before it can
be said deﬁnitively that IL-15 is a potent inducer of mucosal
IgA production.
4.3. Cell-Mediated Immunity. Following delivery of plasmids
expressing antigen and IL-15 (10 or 50μg), Xin et al.
demonstrated signiﬁcant increases in antigen-speciﬁc lysis at
E:Tratiosof80:1(∼70% lysis), 20:1 (40% and 35% lysis,
resp.), and 5:1 (30% and 25% lysis, resp.) when compared
to the speciﬁc lysis induced by immunization with only the
antigen-expressing plasmid (∼30%, 20%, and 10% at 80:1,
20:1, and 5:1, resp.). With the exception of the lowest E:T
ratio, their results were similar to those seen when they
deliveredthesame dosesofplasmids expressing IL-12or IL-2
[40]. The delivery of 10μg pIL-15 also signiﬁcantly increased
the DTH response 14 days after immunization compared
to DTH responses induced by immunization with antigen
alone (14 versus 10 ×10−2 mm, resp.). Toka and Rouse
evaluated the ability of codelivered pIL-15 to augment the
number of antigen-speciﬁc IFNγ-secreting CD8+ T cells in
thespleenatboth7and60daysafteraboosterimmunization
and observed 3- and 3.6-fold increases, respectively, in
antigen-speciﬁc CD8+ responses when compared to those
induced by immunization with antigen alone [27]. They
also demonstrated an increased number of tetramer-positive
antigen-speciﬁc CD8+ T cells at 300 days after the boost
(1.67% versus 0.69% of gated cells), but they did not observe
an increase in peptide-speciﬁc lysis compared to antigen
delivery alone.
4.4. Protection against Challenge. Toka and Rouse vaginally
infectedmicewith1 ×107 pfuHSV65daysaftertheirsecond
and ﬁnal immunization with a DNA vaccine. Codelivery
of pIL-15 increased survival from 2/6 mice (DNA vaccine
alone) to 5/6 mice and decreased the viral titer from 1 ×
105 pfu/mL to 1 × 102.5 pfu/mL, though it is unclear in what
tissue/ﬂuid the viral titer was measured.Clinical and Developmental Immunology 7
5.TypeIIFN
Although type I IFNs are frequently thought of as primarily
involved in antiviral immune responses, they have several
other roles as well, including T-cell proliferation, NK cell
activation, and cytokine induction [52]. Interestingly, pre-
vious studies have linked the adjuvant activities of a TLR9
agonist (IC31) [53] and complete Freund’s adjuvant [54]t o
t h ep r e s e n c eo fI F N A R 1 .
5.1. Serum Antibody Production. Type I IFN nasal vaccine
adjuvant activity has primarily been investigated when
codelivered with inﬂuenza antigens [15, 33, 34]. Using 5 or
11.75μg of hemagglutinin, respectively, Bracci et al. [33]a n d
Proietti et al. [34] demonstrated increased anti-HA serum
IgGandIgG2atwoweeksafterthesecondoftwovaccinations
compared to HA delivered alone. Bracci et al. demonstrated
serum anti-HA IgG increases from ∼1:200 to ∼1:35,000
and serum IgG2a from undetectable to ∼1:25,000 when
using 4kU IFN as a nasal vaccine adjuvant. Likewise,
Proietti et al. observed increases in serum anti-HA IgG
from ∼1:10,000 to ∼1:316,000 and anti-HA IgG2a from
∼1:63to∼1:16,000. Although the dose of IFN delivered by
Proietti in this experiment is unclear, it is evident that type I
IFN can increase serum HA-speciﬁc antibody titers in mice.
Unlike many of the other studies performed with nasally
deliveredcytokineadjuvants,Proiettietal.alsocomparedthe
abilities of type I IFN and MF59 to augment serum antibody
production. Using a 1:1 (v:v) ratio of MF59:antigen, MF59
induced greater amounts of anti-HA IgG1 than type I IFN
(1:30,000 versus 1:10,000, resp.), but it induced less anti-
HA IgG2a and IgA (1:20,000 versus 1:60,000 and 1:20,000
versus 1:130,000, resp.).
Couchetal.evaluatedtheeﬀectivenessoftypeIIFNasan
adjuvant to an inﬂuenza vaccine in both mice and humans
[55]. Although 10kU IFN provided adjuvant activity com-
parable to 5μgC T Bo r7 . 5 μgM P Li nm i c eg i v e n0 . 3 μg
HA on days 0, 1, 28, and 29 (GMT neutAb: 1:49–1:64
versus 1:5 for HA alone), it did not provide signiﬁ-
cant adjuvant activity in humans when given at 10 million
units. However, in the human study, the vaccine was only
administered intranasally once, and it used a diﬀerent
vaccine antigen (HA versus inactivated trivalent inﬂuenza
vaccine). As the inactivated trivalent inﬂuenza vaccine alone
was immunogenic in humans and resulted in elevated serum
anti-HA antibody responses after nasal immunization, it is
possible that the superior immunogenicity of the inactivated
vaccine masked the adjuvant activity of IFN. Within the
mouse model, type I IFN does appear to induce signiﬁcant
increases in antigen-speciﬁc antibody titers, but more in-
depth studies in larger animal models may indicate whether
type I IFN would be an eﬀective intranasal adjuvant in
humans.
5.2. Mucosal Antibody Production. The ability of type I
IFNs to augment mucosal antibody production has not
been frequently evaluated, but the results are encouraging.
When vaccinating mice with 11.75μgH Aa n d4 0 k U I F N ,
Proiettietal.observeda10-foldincrease inBALanti-HA‘IgA
compared to anti-HA IgA induced by immunization with
antigen alone (1:6,300 and 1:630, resp.). In anesthetized
mice,Braccietal.didnotobservesigniﬁcantincreasesinBAL
anti-HA IgA following two immunizations with 5μgH A+
40kUIFN (<1:10) compared to antigen alone, but they
did detect a signiﬁcant increase following the same dosing
regimen in unanesthetized mice (1:40 versus undetectable
for HA alone). Using 4 and 40kUIFN + HA, nasal lavage
anti-HA IgA was signiﬁcantly increased above antigen alone-
induced anti-HA IgA in both anesthetized (1:300 versus
1:100) and unanesthetized (1:550 versus undetectable)
mice, respectively, but the increase was greater in the latter
group. The eﬀects of anesthesia on nasal vaccine-induced
antigen-specific immunity have been previously examined
[21, 56]. Although these studies have demonstrated that
sedation typically correlates with increased antigen-speciﬁc
immunity in serum, Janakova et al. did not observe an
impact on antigen-speciﬁc saliva or fecal IgA production
[56]. The results reported by Bracci et al. are therefore inter-
esting but could be explained, perhaps, by the sites at which
the mucosal responses were evaluated.
Couch et al. also investigated mucosal antibody produc-
tion following vaccination of mice and humans. In mice,
although they evaluated the H1N1 vaccine alone or com-
bined with CTB, MPL, or type I IFN, only vaccination with
HA and MPL induced signiﬁcant increases in lung antigen-
speciﬁc antibody and no group induced signiﬁcant increases
in nasal secretion antibody production compared to HA
alone. Their results were similar in humans, with no signif-
icant increases in antigen-speciﬁc nasal secretion IgG or IgA
when IFN was included in the vaccine compared to vaccine
alone.
5.3. Protection against Challenge. Although type I IFNs have
been evaluated for their ability to protect against challenge,
they have only been evaluated for their ability to protect
against challenge with inﬂuenza virus. Following challenge
with 10 LD50 of inﬂuenza virus, both 4 and 40kUIFN were
found to provide 100% protection compared to 40% and
60% protection after immunization with vaccine alone ([33]
and [34], resp.). In another study, Couch et al. evaluated the
ability of four intranasal vaccinations with 10kUIFN and
0.3μg HA to increase mouse survival following challenge
with 100 ID50 of inﬂuenza virus [55]. Inclusion of IFN in
the vaccine formulation decreased the viral lung titer from
6.2log10/lung to 2.0log10/lung, which was similar to the
other two tested adjuvants, CTB (2.6log10/lung) and MPL
(2.2log10/lung). These studies suggest that type I IFNs can
be eﬀective at increasing vaccine-induced protection against
inﬂuenza viruses.
6.MIP-1α/MIP-1β
Like many cytokines, the MIP-1 family of chemotactic cy-
tokines are known best for their roles in innate immune re-
sponses, including the recruitment of proinﬂammatory cells
[57]. However, they also have the ability to modulate Th8 Clinical and Developmental Immunology
diﬀerentiation, as MIP-1α has been shown to promote Th1
responses [57], and blocking MIP-1α has been shown to
reduce Th1 responses to Cryptococcus neoformans infection
[58].
6.1. Serum Antibody Production. The ability of MIP-1α to
induce serum antibodies has been investigated using at least
two diﬀerent antigens: ovalbumin and HIV-REV [32, 59].
Using plasmid-expressed MIP-1α,L ue ta l .d e m o n s t r a t e d
increased serum anti-HIV IgG, with signiﬁcantly decreased
IgG1 and signiﬁcantly increased IgG2a compared to the
pCMV160IIIB/REV plasmid alone four weeks following a
single administration to mice [59]. The absolute increase in
titer was low, however, with serum anti-HIV IgG increasing
from 1:147 to 1:416; anti-HIV IgG1 and IgG2a titers were
only reported as ODs at an unspeciﬁed dilution. Recom-
binant MIP-1α coadministered with ovalbumin has also
been shown to induce serum antibody production in mice
[32]. A dose of 1μgr M I P - 1 α signiﬁcantly increased serum
anti-OVA IgM and IgG titers above those induced by OVA
alone, though the largest increase was in anti-OVA IgG,
from approximately 1:128 to 1:131,072. This dose of MIP-
1α signiﬁcantly increased all anti-OVA IgG subclasses over
those induced by OVA alone, with the greatest increases in
IgG1(∼1:128versus ∼1:131,072)andIgG2b(∼1:64versus
∼1:8,192), followed by IgG2a (<1:32versus∼1:1,024) and
IgG3 (<1:32versus∼1:128). Although the study by Lu et
al. did not observe drastic increases in serum anti-HIV IgG,
the study by Lillard et al. [32] indicates that MIP-1α shows
promise as a vaccine adjuvant for increasing serum antigen-
speciﬁc antibody production.
In contrast to MIP-1α, Lillard et al. saw a diﬀerent proﬁle
of antibody responses when they used MIP-1β as an adju-
vant. MIP-1β induced levels of serum anti-OVA IgA, IgG,
and IgE by day 21 that were signiﬁcantly greater than those
induced by OVA alone (1:128, 1:32,768, and 1:512, resp.)
[32]. Interestingly, MIP-1β induced smaller increases in
serum anti-OVA IgG1 and IgG2b than MIP-1α (1:32,768
and 1:1,024, resp.), but it did not induce any increases in
anti-OVA IgG2a or IgG3.
6.2. Mucosal Antibody Production. Of the two studies that
have examined nasal delivery of MIP-1α as a vaccine adju-
vant, both have investigated its ability to augment mucosal
antibody responses. Lu et al. observed a signiﬁcant increase
in fecal anti-HIV IgA following intranasal administration
of an HIV plasmid plus 10μgo fp M I P - 1 α compared
to fecal anti-HIV IgA responses induced by immunization
with HIV plasmid alone (1:294 versus 1:91, resp.) [59].
Similarly, Lillard et al. demonstrated a signiﬁcant increase
in fecal (1:77), vaginal (1:23), and nasal (1:9) anti-OVA
IgA in mice given 75μgO V A+1 μgr M I P - 1 α compared
to IgA responses induced in mice administered OVA alone
(<1 : 2 ) ,t h o u g ht i t e r so f1 : 2 3a n d1 : 9a r en o tl i k e l yt o
be biologically signiﬁcant [32]. Lillard et al. also evaluated
the number of ASCs in the nasal tract, lung, and intestinal
lamina propria (ILP). The inclusion of rMIP-1α in the vac-
cine formulation signiﬁcantly increased the number of nasal
OVA-speciﬁc IgM, IgG, and IgA ASCs compared to OVA
alone to 200–250 ASCs/106 cells from 100, 50, and 50 ASCs/
106 cells, respectively. Lung OVA-speciﬁc IgM (∼250 versus
<50 ASCs/106 cells), IgG (∼100 versus <50 ASCs/106 cells)
and IgA (∼50 versus <10 ASCs/106 cells) ASCs as well as
ILP OVA-speciﬁc IgA ASCs (∼350 versus undetectable) were
alsoincreasedbyvaccinationwithOVA+rMIP-1αcompared
to OVA alone. It, therefore, appears that MIP-1α can eﬀec-
tivelyinducemucosalIgAresponses tocodeliveredantigenin
mice.
I nt h es a m es t u d y ,L i l l a r de ta l .a l s oc o m p a r e dr M I P - 1 α
to rMIP-1β [32]. Including 1μgM I P - 1 β in the formulation
induced nearly twice the amount of anti-OVA IgA produc-
tion as MIP-1α in feces, vaginal washes, and nasal washes
(1:152, 1:61, and 1:15, resp., for MIP-1β)[ 32]. However,
the eﬀect on the numbers of OVA-speciﬁc AFCs was not as
great in comparison to MIP-1α.I nt h en a s a lt r a c t ,l u n g s ,
and spleen, the two proteins induced similar amounts of
OVA-speciﬁc IgM-, IgG-, and IgA-secreting cells, but MIP-
1β induced a greater number of IgA-secreting cells in the ILP
(MIP-1α: ∼350/106 AFCs, MIP-1β: ∼600/106 AFCs).
6.3.Cell-Mediated Immunity. BothMIP-1αandMIP-1β pro-
teins have been shown to augment cell-mediated immunity
when used as nasal vaccine adjuvants. Codelivering 1, 10, or
50μgp M I P - 1 α with a DNA vaccine signiﬁcantly increased
the DTHresponse two weeks after immunization(13.6,15.6,
and 11.5 × 10−2 mm) when compared to DTH responses
inducedbyimmunizationwiththeDNAvaccinealone(9.2×
10−2 mm) [59]. Lu et al. were also able to demonstrate that
MIP-1α induced a signiﬁcant increase in antigen-speciﬁc
lysis using splenocytes at E:T ratios of 80:1 and 20:1
(40% and 25%) when compared to responses induced by
immunization with antigen alone (<10% lysis). Following
thedeliveryof1μgr MIP -1αor1μgrMIP -1β threetimeswith
75μg OVA, Lillard et al. demonstrated signiﬁcant increases
in CD4+ T-cell proliferation in the spleen, Peyer’s patches
(PPs), lower respiratory tract, and cervical lymph nodes one
week after the ﬁnal immunization (10–12% proliferating
cells) when compared to proliferative responses induced by
immunization with antigen alone (<2%). Although Lillard
et al. and Lu et al. saw similar increases in mucosal and
systemic CTL for MIP-1α, the inclusion of MIP-1β did not
signiﬁcantly enhance the induction of mucosal or systemic
CD8+ CTLs [32]. MIP-1α increased antigen-speciﬁc target
cell lysis by CD8+ cells isolated from the spleen, CLNs, and
PPs to near 50% at an E:T ratio of 50:1, compared to
0% speciﬁc lysis in mice immunized with antigen alone.
By contrast, MIP-1β increased target cell lysis to only 10%
at 50:1 in the spleen and failed to increase it at the
other sites [32]. Similar to the other immune responses
examined, these two proteins appear to have diﬀering
eﬀects on cell-mediated immunity, with MIP-1α perhaps
being more eﬀective adjuvant for inducing these responses.
However, with only one study examining this eﬀect of
MIP-1β, it is impossible to draw concrete conclusions, and
the two proteins should be evaluated more indepth in the
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7.GM-CSF
As a stimulating factor, GM-CSF induces the proliferation of
macrophage, erythroid, granulocyte, eosinophil, megakary-
ocyte, and multipotent progenitors [60]. However, its recep-
tor is also expressed on monocytes, macrophages, granulo-
cytes, and lymphocytes, and GM-CSF is required for the in
vitro diﬀerentiation of DCs [60].
7.1. Serum Antibody Production. Several studies have dem-
onstrated that GM-CSF is able to increase antigen-speciﬁc
serumantibody productionfollowingintranasal vaccination.
Okada et al. delivered 2μgo faD N Av a c c i n ew i t h2 μgo f
plasmid GM-CSF (pGM-CSF) and liposomes on days 0, 7,
and 21 [30]. Using this procedure, the use of pGM-CSF sig-
niﬁcantly increased anti-HIV serum IgG production on day
28, with a fourfold increase in serum titer compared to anti-
gen plus liposomes alone (1:16,000 versus 1:4,000). This
group also compared the ability of CT to augment immune
responses when coadministered with the DNA vaccine in the
absence of the liposomes and found no signiﬁcant increase
compared to antigen plus liposomes. Unfortunately, because
CT was not administered with the liposome formulation, it
is impossible to compare the adjuvant activities of CT and
GM-CSF in this study. Okada did demonstrate, however,
that pGM-CSF had a superior capacity to increase anti-HIV
IgG compared to an identical dose of pIL-12 [30]. Using a
diﬀerent approach, Kim et al. evaluated the ability of GM-
CSF to augment immune responses when expressed by an
adenoviral vector [61]. In this study, mice were immunized
fourtimesonatriweekly basiswith1 ×108 pfuofadenovirus
expressing amyloid β (aβ) with or without 1 × 108 pfu of an
adenoviralvectorexpressingGM-CSF.Miceimmunized with
the GM-CSF-expressing adenovirus had increased anti-aβ
serum IgG, IgG1, and IgG2b (∼20μg/mL) compared to mice
receiving the aβ-expressing adenovirus alone (negligible).
They also reported small (<5μg/mL) increases in anti-aβ
IgG2a and no increases in anti-aβ IgM compared to the aβ-
expressing adenovirusalone. Incontrast to these twostudies,
which both used vectors expressing GM-CSF, Bradney et
al. delivered 4μgr G M - C S Fw i t h1 0 μg of an HIV peptide
on days 0, 7, 14, and 28. GM-CSF signiﬁcantly increased
serum antipeptide IgG responses (1:10,000) compared to
antigen alone (<1:10), and the increase was comparable to
that induced by 1μg CT (1:10,000). Taken together, these
mouse studies indicate that GM-CSF is an eﬀective adjuvant
forinducingantigen-speciﬁc serumimmuneresponses when
delivered nasally.
One group evaluated the ability of GM-CSF to aug-
ment neutralizing antibody titers [62]. However, following
immunization with 5 × 105 pfu of an attenuated vesicular
stomatitis virus expressing GM-CSF, no increase in VSV-
neutralizing antibody titers was seen compared to a similar
virus expressing EGFP (3,413 versus 2,560, resp.). However,
as this is the only study known to us that has exam-
ined neutralizing antibody production following intranasal
immunization with GM-CSF, it is diﬃcult to say whether a
diﬀerent delivery method (e.g., recombinant protein) would
result in neutralizing antibody production.
7.2.Mucosal AntibodyProduction. Okadaetal.delivered2μg
of a DNA vaccine with 2μg of pGM-CSF and liposomes on
days 0, 7, and 21 [30]. Using this procedure, they demon-
strated a signiﬁcant increase in anti-HIV fecal IgA produc-
tion on day 28 compared to fecal IgA responses induced by
immunization with antigen plus liposomes (1:16,000 versus
1:5,700). When they compared the ability of CT to augment
fecal IgA production after immunization with DNA vaccine
in the absence of the liposomes, they found no signiﬁcant
increase compared to antigen plusliposomes. Unfortunately,
because CT was not administered with the liposome formu-
lation, it is impossible to compare the adjuvant activities of
CT and GM-CSF in this study.
7.3. Cell-Mediated Immunity. Following two intranasal ad-
ministrations of 0.2μgD N Av a c c i n ea n d0 . 2μgp G M - C S F ,
Okada et al. observed no signiﬁcant increase in antigen-
speciﬁc footpad swelling compared to footpad swelling in
mice immunized with DNA vaccine alone (15.8 versus 14.3
× 10−2 mm) [30]. This study also evaluated the ability
of pGM-CSF to enhance antigen-speciﬁc target cell lysis
when added to a vaccine formulation containing pIL-12 +
antigen. The addition of pGM-CSF signiﬁcantly increased
speciﬁc lysis at E:T ratios of 25:1 and 5:1 (∼50% and
28%, resp.) compared to the lytic responses measured after
immunizationwiththepIL-12+antigenformulation(∼40%
and 18%, resp.). Unfortunately, the ability of pGM-CSF by
itself to increase immune responses above those induced by
antigen alone was not evaluated. We determined that rGM-
CSF did not provide adjuvant activity for the induction
of peptide-speciﬁc CTL because there was no increase in
peptide-speciﬁc CTL with the use of rGM-CSF versus CTL
responses induced by immunization withantigen alone [39].
Despite the lack of eﬀect on antigen-speciﬁc CTL responses,
rGM-CSF signiﬁcantly increased the number of peptide-
speciﬁc IFNγ-secreting cells as compared to responses
induced by immunization with antigen alone (∼150 versus
∼10 per 106 splenocytes, resp.) as well as the number
of tetramer-positive CD8+ T cells (∼1.5% versus <0.5%,
resp.) [39]. Interestingly, similar to the results we reported
for the addition of rIL-12 to the vaccine formulation,
boosting allgroupswithantigenaloneonday42signiﬁcantly
increased the eﬀect of rGM-CSF on the induction of target
cell lysis (∼25%), increasing it to levels equal to those
induced by CT (∼30%) and IL-1α (∼25%) (<5% by antigen
alone). Ramsburg et al. also evaluated the ability of GM-
CSF to increase CD8+ T-cell responses [62]. Unlike the
other studies, however, they created an attenuated vesicular
stomatitis virus (VSV) expressing GM-CSF. Compared to a
virus expressing EGFP, GM-CSF increased the number of
VSV tetramer-positive CD8+ T cells in the lungs (28.2%
and 16.3%, resp.) 30 days postinfection. They also noted
that VSV-GMCSF1 increased the ability of those T cells to
expand after a booster immunization compared to VSV-
EGFP.
7.4. Protection against Challenge. At least two studies have
evaluated the ability of GM-CSF to increase protection10 Clinical and Developmental Immunology
against challenge. Similar to the work described by Rams-
burg et al. with a GM-CSF-expressing VSV, Parker et al.
constructed a GM-CSF-expressing HSV-1 and evaluated its
ability to protect against challenge with 1 × 106 pfu HSV
[42]. The expression of GM-CSF by the virus induced HSV-
1-speciﬁc immune responses that signiﬁcantly increased
survival compared to sham-immunized animals when mice
were immunized with 10,000 or 100,000pfu (22/38 and
39/39 surviving, resp.); immunization with 10,000 or
100,000pfu of HSV-1 vaccine lacking GM-CSF induced
survival of 12/39 and 34/40 mice, respectively. Compared
to IL-12 (as discussed above), GM-CSF expression required
higher immunization doses to induce protection. Nambiar
e ta l .u s e das i m i l a rm o d e la n di m m u n i z e dm i c ew i t h
5 × 105 c f uB C Ge x p r e s s i n gG M - C S Fa n de v a l u a t e dt h e
bacterial load after an aerosol challenge with M. tuberculosis
(unknown dose) [63]. Immunization with GM-CSG/BCG
signiﬁcantly decreased (∼1 log reduction) the bacterial load
in the spleen compared to immunization with noncytokine-
secreting BCG when mice were challenged at 4 or 12
weeks following vaccination; lung CFUs were only decreased
when mice were challenged at 4 weeks after immunization
(∼1.5log reduction versus ∼0.5log reduction at 12 weeks).
8.IL-6
Although IL-6 is a potent inﬂammatory cytokine [64], it has
also been shown to play a role in shaping adaptive immune
responses as both a B-cell stimulating factor [64]a n da sa
Th17-inducing cytokine [65].
8.1. Serum Antibody Production. At least two groups have
evaluated the ability of IL-6 to augment serum antibody
production following intranasal immunization. Following
three immunizations with 109L. lactococcus expressing TTFC
and IL-6, Steidler et al. demonstrated signiﬁcantly increased
production of serum anti-TTFC IgG by day 24 that persisted
to at least day 80 when compared to serum anti-TTFC
IgG titers induced by immunization with L. lactococcus
expressing antigen alone (∼1 log increase). Although the
use of IL-6 as an adjuvant increased serum IgG titers, IL-
6 expression did not appear to alter the proﬁle of serum
anti-TT IgG subclasses [23]. Additionally, serum anti-TTFC
IgA production appeared to be increased by the inclusion of
IL-6 compared to antigen alone; whether these diﬀerences
were signiﬁcant is unclear (∼1:100 versus ∼1:40 at day
80). Using a diﬀerent model of delivery, IL-6-containing
liposomes, Boyaka et al. also demonstrated signiﬁcantly
increased serum anti-TT IgG after three immunizations and
a total of six 1μg IL-6 doses compared to antigen alone
(∼1:1,048,576versus1:4,096,resp.) [25].This regimen also
signiﬁcantly increased serum anti-TT IgG1 and IgG2b over
that induced by antigen alone (approx. 1:1,024 compared to
1:128 and 1:64, resp.), butit did not increase IgG2a orIgG3
production.
8.2. Mucosal Antibody Production. Boyaka et al. did not
report increased mucosal IgA production when IL-6 was
included in the vaccine formulation compared to TT alone
[25]. However, they did observe a slight increase in the
number of LPL TT-speciﬁc IgA AFCs induced by TT + IL-
6 when compared to immunization with TT alone (140 and
23 AFCs, resp.). By contrast, Steidler et al. only investigated
the impact of IL-6 on total mucosal IgA production after
nasal immunization with TTFC and found no change when
compared to mice immunized with TT alone. When Boyaka
compared IL-6 to IL-12 after nasal immunization with TT
[25], IL-12 was superior to IL-6 for inducing mucosal
antibody production following vaccination with identical
doses, as it signiﬁcantly increased anti-TT IgA in fecal,
vaginal, and saliva samples compared to TT alone; the
number of anti-TT IgA AFCs was also increased, although
it is unclear if this was signiﬁcant. In addition to those two
studies, Braciak et al. also evaluated mucosal IgA production
following immunization with an adenovirus (Ad) expressing
IL-6 [66]. Following immunization with 3 × 108 pfu IL-
6-expressing adenovirus, BAL anti-Ad IgA titers increased
threefold over 14 days compared to baseline. Their more
striking observation, however, was the increase in lung anti-
Ad IgA ASCs at days 7 and 14 after immunization compared
to adenovirus not expressing IL-6 (174 versus 38 per 106
lymphocytes and 270 versus < 5p e r1 0 6 lymphocytes, resp.).
Given that two of the three studies observed increases in the
number of antigen-speciﬁc IgA ASCs when using IL-6 as a
nasal vaccine adjuvant, it may be that greater increases in
mucosal IgA production could be seen if the IL-6 or antigen
doses were increased in future studies.
8.3.Protectionagainst Challenge. Followingthreeimmuniza-
tions with 75μg TT on days 0, 7, and 14 with rIL-6 delivered
on days 0, 3, 7, 10, 14, and 17, Boyaka et al. observed in-
creased protection against a systemic challenge with 100
MLDs of TT, with all mice surviving challenge compared to
0 mice immunized with TT alone [25].
9.Flt3Ligand
Flt3 ligand (Flt3L) is expressed by stromal ﬁbroblasts in the
hematopoietic bone marrow environment and T lympho-
cytes, and it has been shown to have eﬀects on the prolifera-
tion and diﬀerentiation of T cells, B cells, NK cells, and DCs
[67].
9.1. Serum Antibody Production. Several studies have eval-
uated the nasal adjuvant activity of Flt3L, but the majority
of these have been carried out by the same group at the
University of Alabama, Birmingham [28, 29, 68]u s i n gO V A
as the codelivered antigen. All three studies used the same
immunization schedule (three times at weekly intervals) and
antigen dose (100μg OVA), but one of the three delivered a
plasmid expressing Flt3L (50μg) [28], the second delivered
plasmids expressing CpG, Flt3L, or CpG plus Flt3L (50μg)
[68], and the third used a Flt3L-expressing adenovirus (1 ×
108 pfu) [29]. When OVA was delivered with either pFlt3L
or Ad-Flt3L, Kataoka et al. and Sekine et al. demonstrat-
ed serum anti-OVA IgG production that was signiﬁcantlyClinical and Developmental Immunology 11
increased above that induced by OVA delivered with an
empty vector (pFlt3L: 1:4,096 versus 1:524,288, resp.; Ad-
Flt3L: 1:8,194 versus 1:131,072, resp.). Both studies also
demonstrated increases in serum anti-OVA IgA production
when Flt3L was coadministered with antigen compared to
IgA responses induced by immunization with antigen alone,
but only the study using the adenoviral vector noted the
diﬀerence as signiﬁcant (pFlt3L: 1:1,024 versus 1:64, resp.,
Ad-Flt3L: 1:2,048 versus <1:64, resp.). When pFlt3L was
codelivered with pCpG and OVA, the serum anti-OVA
antibody production was not signiﬁcantly increased over
pCpG + OVA or pFlt3L + OVA [68]. However, the anti-OVA
IgG subclass proﬁle did diﬀer signiﬁcantly, as OVA-speciﬁc
IgG2a and IgG2b production (1:524,288) was signiﬁcantly
increased over that induced by CpG + OVA (1:65,536) or
pFlt3L + OVA (1: 32,768) and equal to the amounts of anti-
OVA IgG1 induced by any formulation. Using the adenoviral
vector,Sekineet al. also saw signiﬁcant increases in anti-OVA
IgG1, IgG2a, and IgG2b (1:8,192, 1:65,536, and 1:8,192,
resp.) compared to an empty vector (1:1,024, 1:4,096, and
1:1,024, resp.). By contrast, Kataoka et al. did not note a
signiﬁcant increase in anti-OVA IgG2a following vaccination
with OVA + pFlt3L, but they did see signiﬁcantly increased
anti-OVA IgG1 and IgG2b (1:262,144 and 1:16,384, resp.,
versus 1:2,048 and 1:1,024, resp., for antigen alone). Anti-
OVA IgG3 was not increased in any of the studies.
In contrast to those studies, Kodama et al. used an en-
tirely diﬀerent immunization protocol [69]. In their study,
10μg rFlt3L was delivered alone on day 0 and antigen alone
(Haemophilus inﬂuenzae P6) was delivered on days 6, 13,
and 20. This protocol resulted in a signiﬁcant increase in
the number of NALT DCs prior to the ﬁrst delivery of
antigen. At one week following vaccination, serum anti-P6
IgG (1:131,072), IgM (1:64), and IgA (1:64) were signif-
icantly increased with the use of Flt3L when compared to
those induced in mice immunized with P6 alone (1:128,
undetectable, and undetectable, resp.). The increased serum
titers decreased little through three months after vaccination
in mice receiving P6 + Flt3L, but all serum titers were
undetectable in mice given P6 alone. Taken together, these
studies indicate that Flt3L can increase and maintain serum
immune responses to codelivered antigen.
9.2. Mucosal Immunity. The four studies that investigated
the ability of Flt3L to increase serum immune responses also
evaluated its ability to increase mucosal immune responses
[28, 29, 68, 69]. Two studies have demonstrated enhanced
mucosal antibody production following vaccination with
Flt3L. Following delivery of pFlt3L and antigen, Kataoka
et al. signiﬁcantly increased nasal wash and saliva anti-
OVA IgA production (∼1:128 and 1:23, resp.) over that
induced by antigen alone (undetectable). Similarly, Sekine
et al. demonstrated that OVA + Ad-Flt3L increased nasal
wash and saliva anti-OVA IgA production (∼1:32 and
1:16, resp.) compared to OVA + empty vector (∼1:8and
1:6, resp.). Both studies noted increases in the number of
IgA anti-OVA AFCs at various mucosal sites, including the
nasal passages (NPs), submandibular glands (SMGs), lamina
propria (LP), and NALT when compared to anti-OVA IgA
AFCs induced by immunization with OVA alone. Sekine et
al. observed the largest adjuvant eﬀect of Flt3L, with OVA
alone generating few, if any, OVA-speciﬁc IgA AFCs while
OVA + pFlt3L generated 100, 250, and 200 per 106 cells
in the NPs, SMGs, and LP, respectively. Kataoka et al.
demonstrated increases to ∼750, 50, and 40 anti-OVA IgA
AFCs per 106 cells in the NPs, SMGs, and NALT,respectively,
with few, if any, induced by immunization with OVA alone.
In contrast to these two studies, Fukuiwa did not note
any signiﬁcant increases in nasal or saliva anti-OVA IgA
(1:32 and 1:64, resp.) or NP or SMG anti-OVA IgA
AFCs (∼180 and 200 per 106 cells, resp.) when 50μgp F l t 3 L
was delivered with 100μg OVA compared to OVA alone
(undetectable) [68]. When Kodama et al. delivered 10μg
rFlt3L on day 0 followed by three immunizations with 10μg
of P6 antigen alone on days 6, 13, and 20, nasal anti-P6
titers were signiﬁcantly increased by the addition of rFlt3L
compared to immunization with antigen alone at both one
week and three months after immunization (1:64 versus
undetectableatbothtimepoints)[69].Similarly,thenumber
of anti-P6 IgA AFCs was signiﬁcantly increased in the nasal
passages at one week and three months after vaccination
using rFlt3L when compared to IgA AFCs induced by
immunization with antigen alone (∼1,400 and 1,000, resp.,
versus ∼250 per 106 cells). However, they were not increased
in the NALT. Therefore, similar to its ability to induce anti-
gen-speciﬁc serum immune responses, Flt3L does appear
to augment antigen-speciﬁc mucosal antibody responses as
well. The diﬀerencesinAFCsinducedin the various mucosal
sites investigated may be related to the methods in which
Flt3L was administered, for example, plasmid, adenoviral
vector, and recombinant protein.
9.3. Cell-Mediated Immunity. Two of the studies discussed
above have evaluated the ability of Flt3L to increase cell-
mediated immune responses to codelivered antigen. Fol-
lowing immunization with pFlt3L and OVA, Kataoka et al.
demonstrated signiﬁcantly increased splenocyte and CLN
OVA-speciﬁc CD4+ T-cell proliferation seven days after the
ﬁnal immunization compared to OVA + empty vector [28].
Similarly, Sekine et al. evaluated splenocyte and CLN OVA-
speciﬁc CTL activity seven days after the ﬁnal immunization
with Ad-Flt3L [29]. Compared to OVA plus an empty
adenoviral vector, OVA + Ad-Flt3L signiﬁcantly increased
speciﬁc lysis in the CLNs and spleen at an E:T ratio of 25:1
(∼30% and 75%, resp., versus 15% and 30% for OVA + Ad-
luc, resp.).
9.4. Protection against Challenge. In their study, Kodama
et al. evaluated the ability of Flt3L to enhance the clearance
of 108 cfu of a nasally delivered nontypeable Haemophilus
inﬂuenza atoneweek andthree months after theﬁnal immu-
nization [69]. At both time points, the use of Flt3L as an
adjuvant on day 0ofthe immunization protocolsigniﬁcantly
decreased the bacterial load in the nasal cavity by approxi-
mately 2 logs as compared to mice immunized with antigen
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10.IL-1
IL-1 is a potent proinﬂammatory cytokine with a wide range
of eﬀects on the host immune system. These eﬀects include
the up- and downregulation of many genes, including
cytokine and chemokine receptors, cytokines and chemok-
ines, and adhesion molecules, resulting in the traﬃcking of
cell populations (e.g., neutrophils) into areas of inﬂamma-
tion[70].IL-1 hasalso beenshown to playa role in Th17 dif-
ferentiation [71].
10.1. Serum Antibody Production. O u rg r o u pw a st h eﬁ r s tt o
use IL-1as an adjuvantin nasally administered vaccines [72].
WehavesinceusedIL-1withavarietyofcodeliveredantigens
in three animal models: mice [21, 31, 39, 72], rabbits [21],
and monkeys [73]. In our ﬁrst study, we codelivered 4μg
of either IL-1α or IL-1β with 50μg TT or 100μgO V Aa n d
compared the induced immune responses to those induced
by 1μg CT plus antigen. Both IL-1 proteins induced serum
antigen-speciﬁc IgG equivalent to that induced by immu-
nization with CT + antigen. We also evaluated the ability of
CT and IL-1 to enhance serum antibody production when
delivered with all three immunizations or only with the ﬁrst
immunization. Compared to TT delivered without adjuvant,
IL-1 increased serum anti-TT IgG at least 2 log after delivery
with all three immunizations and at least 1.5 log when
delivered only with the ﬁrst immunization [72]. When OVA
wasusedastheantigenandtheadjuvantsweredeliveredwith
all three immunizations, both IL-1α and IL-1β increased
serum anti-OVA IgG to approximately 1:100,000 compared
to <1:1,000 for antigen alone and 1:10,000 for OVA +
CT [72]. When IL-1 was only delivered with the ﬁrst OVA
immunization, it induced anti-OVA IgG titers of 1:10,000,
while OVAalone and OVA+CT (deliveredonlywith the ﬁrst
immunization) induced titers <1:1,000. In general, the anti-
OVA IgG subclass proﬁles were similar between the mouse
strains and adjuvants (i.e., IL-1α,I L - 1 β,a n dC T ) .H o w e v e r ,
when OVA was used as the antigen, IL-1 delivered with
all three immunizations induced greater anti-OVA IgG1,
IgG2a, and IgG2b responses than CT delivered with all three
immunizations. In addition to protein antigens, we have
also evaluated the ability of IL-1 to augment serum antigen-
speciﬁc immune responses to an HIV peptide antigen
[31]. Following three immunizations, codelivery of 4μg
IL-1α increased antipeptide IgG production to ∼1:50,000,
compared to ∼1:10,000 for antigen + CT and <1:10 for
antigen alone. In a recently published study, we evaluated
the ability of IL-1β to induce serum antibody responses to
immunization with TT or pneumococcal surface protein A
(PspA) [21]. When 5μg IL-1 was nasally codelivered with
either PspA or TT, it induced serum antigen-speciﬁc IgG
production equivalent to that induced by a subcutaneous
injection of PspA with alum or an intranasal immunization
with TT + CT. One other group has also evaluatedthe ability
of nasally delivered IL-1 to augment antigen-speciﬁc serum
antibody production [22]. Following immunization on days
0a n d2 8w i t h1μg rHA plus 1μgo fe i t h e rI L - 1 α or IL-1β,
Kayamuro et al. demonstrated signiﬁcantly increased serum
anti-HA IgG when compared to anti-HA IgG titers induced
by immunization with rHA alone, though these responses
were only reported as ODs at an undeﬁned serum dilution.
However, they also compared the IL-1-induced immune
response to that induced by 1μg CT. At a serum dilution
of 1:1,000, CT-induced anti-HA IgG was approximately 1.2
OD450,w h i l eI L - 1 αat0.1–1μg increased anti-HAIgG to 0.7–
1.1OD450.Intheabsenceofadjuvant,HA-inducedresponses
were <0.2 OD450.A l t h o u g hi ti sd i ﬃcult to compare the
magnitude of the responses between their study and ours, it
is evident from the inclusion of CT by both groups that IL-1
increased antigen-speciﬁc serum immune responses to levels
equivalent to those induced by CT.
We have also evaluated the ability of nasally delivered
IL-1 to augment immune responses in rabbits [21]. Unfor-
tunately, the antigen-speciﬁc immune responses induced in
the rabbits were highly variable and did not reﬂect a dose-
responsive relationship with IL-1. When TT + IL-1 was
delivered intramuscularly, the serum anti-TT IgG titer was
signiﬁcantly increased compared to the anti-TT IgG titer
induced by intranasal delivery of TT + IL-1 (1:16,777,226
and 1:1,048,576, resp.).
10.2. Mucosal Antibody. Within the studies discussed above,
we also evaluated the ability of IL-1 to induce mucosal
antibody production. In our ﬁrst study, 4μgI L - 1 α or IL-1β
was codelivered with OVA or TT and compared to 1μgC T
plus OVA or TT as well as antigen alone [72]. We compared
the ability of the adjuvants to augment mucosal immune
responses to the codelivered antigen when delivered only
with the ﬁrst immunization or with all three immunizations.
Regardless of the codelivered antigen (TT or OVA), IL-1 was
able to induce vaginal antigen-speciﬁc IgA when it was code-
livered with antigen all three times (1:50–1:100), whereas
CT was unable to induce vaginal anti-OVA IgA. CT was
able to induce vaginal IgA production following vaccination
with TT, but the increases were still less (not signiﬁcantly)
than those induced by TT + IL-1. In another experiment,
following three immunizations with TT + IL-1β, doses from
0.2 to 5μg IL-1 were able to induce signiﬁcantly increased
vaginal anti-TT IgA (1:512–1:1,448), and the response was
similar to that induced by 1μg CT (1:1,048). Kayamuro
e ta l .h a v ea l s od e m o n s t r a t e dt h ea b i l i t yo fI L - 1 α and IL-
1β to induce mucosal antibody production [22]. Following
immunizations on days 0 and 28, they reported increased
nasal wash anti-HA IgA following vaccination with HA +
CT (1μg) or either IL-1 (0.2–1μg) at dilutions of 1:6 and
1:30(OD 450 ∼ 1.2 and 0.6, resp.) compared to vaccination
with HA alone (OD450 < 0.2). They also demonstrated
signiﬁcantly increased anti-HA IgA in saliva, vaginal, and
fecal samples following immunization with HA + IL-1α or
IL-1β as compared to immunization with HA alone, but
these were reported in OD450 at undeﬁned sample dilutions.
Althoughthe diﬀerent reporting methods make it diﬃcult to
directly compare the studies, IL-1 was shown by all studies
described to increase mucosal immune responses to the
codelivered antigen in mice. Despite the promising results in
mice, IL-1 has not yet been shown to signiﬁcantly enhance
mucosal antigen-speciﬁc antibody production in rabbits.Clinical and Developmental Immunology 13
Although we have evaluated the ability of IL-1 to induce
antigen-speciﬁc vaginal IgA production in rabbits, IL-1-
adjuvanted vaccines did not induce IgA in rabbits under the
conditions tested [21].
10.3. Cell-Mediated Immunity. In the studies discussed
above, we also evaluated the ability of IL-1 to augment cell-
mediated immune responses. In two studies in which we
examined DTH following three intranasal immunizations,
IL-1 signiﬁcantly increased the antigen-speciﬁc ear swelling
response toinjected antigenoverthatinducedbyvaccination
with antigen alone [21, 72]. Compared to CT, IL-1 induced
signiﬁcantly increased ear swelling following immunization
with OVA [72]. However, when codelivered with TT, CT
and IL-1 have been shown to induce similar degrees of ear
swelling in both BALB/c and C57BL/6 mice [72].
We have also evaluated increases in antigen-speciﬁc lym-
phoproliferative responses following immunization with TT
plus adjuvant [72]. IL-1α,I L - 1 β, and CT increased TT-spe-
cific lymphoproliferation to nearly 12,000cpm in C57BL/6
and 16,000–22,000cpm in BALB/c mice, while TT alone
induced little lymphoproliferation. In addition, we have
shown that IL-1α can signiﬁcantly increase target cell lysis
following four immunizations with 100μg HIV peptide and
4μgI L - 1[ 39]. Peptide-speciﬁc lysis at an E:T ratio of 25:1
was increased to 45% with the use of IL-1 as an adjuvant as
compared to ∼15% in mice immunized with antigen alone;
this increase was similar to that induced by CT (∼55%).
In the same study, the number of antigen-speciﬁc IFNγ-
secreting CD8+Tcellswasalso increased withtheuseofIL-1
compared to mice immunized with antigen alone (∼150 per
106 versus ∼10 per 106,r e s p . ) ,w h i l eC Ts h o w e das i m i l a r
increaseto ∼200per106.The%oftetramer -positiveCD8+T
cellswasalso increased (<0.5%versus2.5% forantigenalone
and antigen + IL-1, resp.).
In contrast to the results we have reported, Kayamuro
et al. evaluated the ability of IL-1α and IL-1β to induce HA
tetramer-positive CD8+ T cells and peptide-speciﬁc IFNγ-
secreting CD8+ T cells and failed to observe signiﬁcant
increases [22]. Although IL-1α did slightly increase the
ﬂuorescenceintensityoftetramer-positivecells(∼1.75versus
∼1.1 for HA alone), only CT signiﬁcantly increased this
response (∼2.3). Similarly, HA + IL-1α or HA + IL-1β
did not signiﬁcantly increase the number of IFNγ-secreting
CD8+ T cells compared to HA alone (35, 10, and 5 per 106
splenocytesfor IL-1α,I L - 1 β, and HA, resp.), although in this
instance, neither did immunization with HA + CT (∼25/106
splenocytes) [22]. However, the variation in the response
induced by IL-1α was relatively large. All of these studies
indicate that IL-1 has the ability to augment cell-mediated
immunity, though the magnitude of the induced response
may diﬀer based on the antigen or antigen dose used.
10.4. Protection against Challenge. We have evaluated the
ability of IL-1 to provide adjuvant activity and enhance
vaccine-induced survival following challenge with either
1.125 × 105 cfuS.pneumoniaeor10LD50 TT[21].Intranasal
immunization with PspA and IL-1 signiﬁcantly increased
survival following IV challenge on day 72 to 68% compared
to 0% survival in mice immunized with PspA alone.
This increase was equal to that induced by subcutaneous
administration of PspA + alum (68%). Similarly, intranasal
immunization with 0.2–5μg IL-1 + TT provided 100% pro-
tection following a TT challenge while immunization with
TT alone provided only 10% protection. Kayamuro et al.
also evaluated the ability of IL-1 to enhance vaccine-induced
protection against challenge [22]. They intranasally admin-
istered 256 hemagglutinating units of inﬂuenza virus 14 days
after the second of two immunizations (on days 0 and 28)
and evaluated the ability of 1μg HA alone, HA + 1μgC T ,o r
HA+1μgI L - 1 α orIL-1β to protectagainst morbidity. While
coadministration of CT with HA provided 100% survival,
immunization with HA alone provided only 10% survival.
The use of IL-1 as a nasal vaccine adjuvant provided signiﬁ-
cant protective immunity, as 80–85% of mice survived infec-
tion. Although in this model, IL-1 did not perform as well as
CT, it did signiﬁcantly increase survival following challenge.
11.Other Cytokines
Although this paper attempted to focus on some of the more
well-studied cytokines, other cytokines and chemokines
have been evaluated in one or two studies for their ability
to augment antigen-speciﬁc immune responses following
intranasal vaccination. Among these are RANTES [74, 75],
TNFα [76], IFNγ [77], lymphotactin [78], IL-4 [77], IL-
5[ 66, 79], and IL-18 [22, 31, 39]. Although many of
these have shown promise by inducing antigen-speciﬁc
antibody responses above those induced by immunization
with antigen alone, more studies are required to determine
their real value as intranasally delivered vaccine adjuvants.
For example, two studies have evaluated the nasal adjuvant
activity of RANTES [74, 75] and have demonstrated its abil-
ity to augment serum and mucosal responses to codelivered
OVA when given as a recombinant protein and cell-mediated
immune responses to an HIV DNA vaccine as an expression
plasmid. The same group that delivered rRANTES with OVA
also evaluated lymphotactin and demonstrated its ability
to increase serum anti-OVA IgG, IgA, and IgM at day 21
(one week after the ﬁnal immunization) as well as mucosal
anti-OVA IgA [78]. As another example, we have evaluated
IL-18, an IL-1 family cytokine, for its ability to augment
serum antibody production as well as cell-mediated immune
responses. When 0.4μg IL-18 was delivered nasally with an
HIV peptide, antipeptide IgG was signiﬁcantly increased to
levels equal to those induced by 1μgC T ,4 μgI L - 1 α,a n d
4μgG M - C S F[ 31] .T h i sd o s ew a sa l s oa b l et os i g n i ﬁ c a n t l y
increase peptide-speciﬁc lysis and the number of IFNγ-
secreting CD8+ T cells [39]. However, the induced cell-
mediated immune responses were not as great as those
induced by CT or IL-1α, indicating that a higher dose of IL-
18 may be required for optimal responses. Although many
diﬀerent cytokines have been evaluated as nasal vaccine
adjuvants, it is likely that they will not all be equally as
goodat generatingall desired immune responses. More work
will be required to evaluate the vaccine adjuvants mentioned14 Clinical and Developmental Immunology
to determine if they will in fact be eﬀective at increasing
antigen-speciﬁc immune responses to a variety of antigens
in multiple animal models.
12.CytokineCombinations
Although brieﬂy mentioned above, cytokines have been
used in combination with other cytokines or other vaccine
adjuvants to induce antigen-speciﬁc immune responses. In
several instances, the inclusion of a cytokine that may not
have been eﬀective by itself was enough to signiﬁcantly
increase immune responses when given with another adju-
vant over those provided by either of them alone. In others,
the combination of the cytokine adjuvants provided no
increase in the immune response compared to just one
delivered alone. The latter situation may reﬂect the activities
of those particular cytokines. For example, two groups have
shown that the combination of rIL-12 and rGM-CSF is a
poor inducer of antigen-speciﬁc immunity [30, 39], and the
combination of rIL-12 and rIL-6 was also found to be inef-
fective at increasing immune responses over those induced
by IL-12 alone [25]. However, other cytokine combinations
have shown more promise. We have previously shown that
combinations of IL-1 + GM-CSF, IL-1 + IL-12, IL-1 + IL-
1 8 ,a n dI L - 1+I L - 1 2+G M - C S Fw e r es i g n i ﬁ c a n t l yb e t t e r
inducers of cell-mediated immunity than these cytokines
delivered individually [39]. We have also evaluated the
ability of IL-1 + GM-CSF to augment antipeptide immune
responses following intranasal immunization of macaques
[73]. In this study, we demonstrated that IL-1 + GM-CSF
inducedantibodyproductioninthenasalandgenitalmucosa
following codelivery with an HIV peptide, while a mutant
CT did not. However, parenteral delivery of GM-CSF in
combination with an MPL analog (RC-529) and antigen
elicited stronger responses than intranasal delivery.
Two other groups have combined cytokine adjuvants
with more common mucosal adjuvants, such as CTB and
CpG [38, 68]. Using 1μgI L - 1 2a n d1 0μgC T Bc o d e l i v e r e d
with gp120, Albu et al. observed that only the combination
of the two increased immune responses over those induced
by antigen alone or antigen with either IL-12 or CTB [38].
Similarly, although both CpG and pFlt3L alone induced
increases in antigen-speciﬁc immune responses, Fukuiwa et
al. demonstrated that the combination of the two induced
more potent mucosal IgA production and serum anti-OVA
IgG2a and IgG2b than either of them delivered alone [68].
As many noncytokine adjuvant combinations have recently
been evaluated (e.g., GlaxoSmithKline’s adjuvant systems)
and the combination of alum and MPL has recently received
FDA approval for parenteral delivery [80], more in-depth
studies will be valuable in determining just how combi-
nations of cytokine adjuvants will be useful for increasing
speciﬁc immune responses in multiple animal models.
13.SafetyofNasally Administered Vaccines
Toxins and toxin derivatives are not the only current safety
concern for nasal vaccines. Many groups have expressed
concern about the potential for nasal vaccines to result
in the delivery of nasal vaccine antigens or adjuvants into
the brain. Several studies have examined the ability of
various compounds to enter the brain after nasal deliv-
ery and have compared nasal to systemic routes of immu-
nization. Although many compounds, such as interferon,
have the ability to enter the olfactory bulb and the brain
after nasal delivery [81], few side eﬀects were observed
following nasal immunization with an aerosolized measles
vaccinelackingtoxinadjuvantsinhumans[82].Additionally,
the live-attenuated, nasally administered inﬂuenza vaccine,
FluMist, has been approved by the FDA and is considered
safe [83]. Although the signiﬁcance of enterotoxin delivery
or redirection of vaccine antigens to the olfactory bulb is
unclear, it is evident from the development of Bell’s palsy
following vaccinationwithmutantLTthatsafermucosalvac-
cine adjuvants are required for use in human vaccines[16].
Additional studies are needed to carefully evaluate local and
systemic toxicity after nasal immunization using cytokine
adjuvants.
14.Conclusions
As demonstrated in this paper, many cytokines have been
evaluated as adjuvants for their ability to augment antigen-
speciﬁc immune responses following nasal delivery. It is
evident,however, that more work is required before cytokine
adjuvants can be said deﬁnitively to be potent vaccine adju-
vantsforanyoftheresponses discussedabove.Itisimportant
to always consider the methods of antigen and adjuvant
delivery (e.g., recombinant proteins, plasmids) as well as the
types of antigen being used when evaluating any adjuvants
for their eﬀectiveness. Nonetheless, cytokines have so far
shown promising results when given nasally with a variety of
vaccineantigensandhavetheabilitytoinducemanydiﬀerent
types of immune responses. As such, cytokines may be ideal
for inclusion in vaccines in which only certain immune
responses are desired. In the future, more studies need to
evaluatecytokineadjuvantswithrespect tootherwell-known
vaccine adjuvants, such as CT or TLR ligands, to give study
results more meaning with respect to the already published
literature.
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